Arrhythmias and Conduction DisturbancesEffect of Age on Survival and Causes of Death After Primary Prevention Implantable Cardioverter-Defibrillator Implantation
Section snippets
Methods
All patients with coronary artery disease or dilated cardiomyopathy implanted with an ICD for primary prevention of SCD at 12 centers (9 university hospitals and 3 private centers) in France from January 2002 through January 2012 were included in this retrospective, observational, single-center study (Défibrillateur Automatique Implantable en Prévention Primaire [DAI-PP]). Patients were implanted in the setting of primary prevention (no previous episode of sudden cardiac arrest or arrhythmic
Results
Of the 5,539 ICD recipients in this registry, age was known in 99.9% (n = 5,534): 38.7% were aged 18 to 59 years, 48.7% 60 to 74 years, and 12.7% ≥75 years (Table 1). The prevalences of coronary artery disease and atrial fibrillation, and the median ejection fraction, increased with higher age group (all p values <0.0001). The prevalence of noncardiovascular co-morbidities (lung disease, liver disease, cancer) also increased with older age. Older patients (≥60 years) were more likely than
Discussion
In view of the aging population, the use and associated outcomes of ICD implantation in elderly patients for the primary prevention of SCD is gaining interest. In this population-based French registry of patients who underwent new ICD implantation in routine clinical practice, nearly 50% of patients were ≥60 years and 13% were ≥75 years. Older patients (≥60 years) had a greater risk profile than younger patients and were more likely to receive a cardiac resynchronization therapy defibrillator
Acknowledgment
The authors thank the investigators of the enrolling centers for participating in the study and sharing their data; the Research Assistants and Associates Frankie Beganton, MS, Nicolas Estrugo, MS, Sandrine Hervouet, MS, Nathalie de Carsin, MS, Radu Mosei, MD, Frederic Treguer, MD, Juliette Tennenbaum, MD, Raoul Hubac-Coupet, MD, Alexandre Bendavid, MD and Marine Sroussi, MD, for collecting the data; and the Arrhythmia Group of the French Society of Cardiology for supporting this project. Mrs
References (27)
- et al.
Effect of cardiac and noncardiac conditions on survival after defibrillator implantation
J Am Coll Cardiol
(2007) - et al.
Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death
Am Heart J
(2004) - et al.
Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy in a real-world setting: data from the Israeli ICD Registry
Heart Rhythm
(2014) - et al.
Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database
J Am Coll Cardiol
(2010) - et al.
Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction
J Am Coll Cardiol
(2008) - et al.
Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study
J Am Coll Cardiol
(2007) - et al.
Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death
J Am Coll Cardiol
(2012) - et al.
Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality
J Am Coll Cardiol
(2011) - et al.
Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?
Am J Cardiol
(2006) - et al.
Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study
J Am Coll Cardiol
(2008)
Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death
Am J Cardiol
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
N Engl J Med
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy
N Engl J Med
Cited by (0)
Funding: This work was supported by the following independent institutions: the Toulouse Association for the Study of Rhythm Disturbances; the French Institute of Health and Medical Research; and the French Society of Cardiology.
See page 1421 for disclosure information.
- †
The full list of investigators is detailed in Appendix 1.